Home >> Public Health >> Pharmaceuticals >> Food & Beverage >>

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013

Published: Dec-2013 | Format: PDF | Global Markets Direct | Number of pages: 38 | Code: MRS - 829

Global Markets Directs, 'Fibrinogen Deficiency (Factor I Deficiency) Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Fibrinogen Deficiency (Factor I Deficiency) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency).
A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency).
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrinogen Deficiency (Factor I Deficiency) Overview 6
Therapeutics Development 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis 8
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 9
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 13
Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 14
Biotest AG 14
Pharming Group N.V. 15
Octapharma AG 16
LFB S.A. 17
China Biologic Products, Inc. 18
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
Human Fibrinogen - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fibrinogen human - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Octafibrin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Human Fibrinogen Concentrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Human Fibrinogen - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 32
Featured News & Press Releases 32
Dec 19, 2012: CSL Behring's Fibrinogen Concentrate Given As First-Line Therapy Safely Reduces Need For Transfusion After Aortic Surgery In Phase II Study 32
Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 33
Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 33
Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 34
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 35
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval Of Human Fibrinogen Concentrate For The Treatment Of Congenital Bleeding 35
Mar 02, 2006: Biotherapix And Digna Biotech Announce Collaboration For Novel Therapeutics 36

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38


List of Tables

Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H2 2013 7
Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Biotest AG, H2 2013 14
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Pharming Group N.V., H2 2013 15
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Octapharma AG, H2 2013 16
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by LFB S.A., H2 2013 17
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by China Biologic Products, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Route of Administration, H2 2013 22
Number of Products by Stage and Molecule Type, H2 2013 24
Number of Products by Stage and Therapeutic Class, H2 2013 26 

List of Figures


Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H2 2013 7
Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 11
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Route of Administration, H2 2013 21
Number of Products by Stage and Top 10 Route of Administration, H2 2013 22
Number of Products by Top 10 Molecule Type, H2 2013 23
Number of Products by Stage and Top 10 Molecule Type, H2 2013 24
Number of Products by Top 10 Therapeutic Class, H2 2013 25
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 26 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing